Pembrolizumab is the first approved immunotherapy agent, and its mechanism of action is based on preventing the interaction of programmed cell death protein-1 (PD-1) with program cell death ligand-1 (PD-L1) and program cell death ligand- 2 (PDL-2) and restoring anti-tumor immunity [23]. The gene discussed is PDCD1; the disease is neoplasm.